3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
9
Recruiting
4
Active not recruiting
3
Withdrawn
2
Unknown
2
Terminated
1
Suspended
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
52
Brain Neoplasms
28
Glioma
22
Gliosarcoma
19
Melanoma
18
Astrocytoma
17
Central Nervous System Neoplasms
11
Oligodendroglioma
10
Neoplasms
9
Neoplasm Metastasis
8
Recurrence
6
Carcinoma, Non-Small-Cell Lung
5
Neuroblastoma
4
Lymphoma
4
Ependymoma
4
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neurologic Manifestations
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Second Primary
2
Meningeal Carcinomatosis
2
Medulloblastoma
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocytopenia
1
Tetanus
1
Spinal Cord Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Recurrent
1
Interventions
Doxorubicin
13
Gemcitabine
10
Cyclophosphamide
10
pazopanib
8
Filgrastim
8
Radiotherapy
7
Ifosfamide
7
Cisplatin
7
Irinotecan
6
Docetaxel
6
Radiation
5
Granulocyte Colony-Stimulating Factor
5
Etoposide
5
Trabectedin
4
Magnetic Resonance Spectroscopy
4
Celecoxib
4
Busulfan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
sargramostim
3
pembrolizumab
3
X-Rays
3
Sirolimus
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Neoadjuvant Therapy
3
Leucovorin
3
Dexrazoxane
3
Cryosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts